Dr. Sigrun Hallmeyer, MD
Claim this profileAdvocate Lutheran General Hospital
Studies Breast Cancer
Studies Skin Cancer
13 reported clinical trials
22 drugs studied
Area of expertise
1Breast Cancer
Stage II
HER2 positive
Stage III
2Skin Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Sigrun Hallmeyer, MD is currently running
Surgical Excision Margins
for Melanoma
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Recruiting1 award N/A9 criteria
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
More about Sigrun Hallmeyer, MD
Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Sigrun Hallmeyer, MD has experience with
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Wide Local Excision = 1cm Margin
- Wide Local Excision = 2cm Margin
- Relatlimab
Breakdown of trials Sigrun Hallmeyer, MD has run
Breast Cancer
Skin Cancer
Cancer
Breast cancer
Cutaneous Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Sigrun Hallmeyer, MD specialize in?
Is Sigrun Hallmeyer, MD currently recruiting for clinical trials?
Are there any treatments that Sigrun Hallmeyer, MD has studied deeply?
What is the best way to schedule an appointment with Sigrun Hallmeyer, MD?
What is the office address of Sigrun Hallmeyer, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.